INTRODUCTION
============

Bronchial asthma is characterized by airway inflammation, reversible airway obstruction and airway hyperresponsiveness \[[@B1]\]. Although numerous cell types are involved in airway inflammation associate with asthma, eosinophils play an important role in asthma pathogenesis through the release of inflammatory mediators, such as specific granule proteins, reactive oxygen species, cysteinyl leukotrienes and cytokines \[[@B2]\].

Adaptive immune responses are involved in the development of allergies or allergic diseases such as bronchial asthma \[[@B3][@B4]\]. When patients are exposed to a specific allergen, dendritic cells present it to naïve T cells, and activating them as they polarize into T helper type 2 (Th2) cells \[[@B3]\]. Activated Th2 cells produce cytokines, such as interleukin (IL)-4 and IL-13, which promote the production of the allergen-specific immunoglobulin (Ig) E from B cells, and IL-5 that activates eosinophils. Among the allegens, house dust mite (HDM) is a significant cause of allergic disease including bronchial asthma \[[@B5]\]. *Dermatophagoides farina* (*Df*) and *Dermatophagoides pteronyssinus* (*Dp*) are important HDMs, and Der f 1 or Der p 1 is a major allegen of *Df* or *Dp* \[[@B5][@B6]\]. HDM play important role in the development of allergic sensitization and disease \[[@B7][@B8]\]. Furthermore, HDM exposure exacerbated allergic symptoms including asthma attacks in the case of sensitized patients.

However, innate immune responses also contribute to the development of allergic disease \[[@B4][@B5][@B9][@B10][@B11]\]. For example, the role of type 2 innate lymphoid cells (ILC2) in severe asthma has recently been established \[[@B9]\]. Furthermore, even in subjects who are not sensitized to HDM or pollen, allergic symptoms can be clinically induced or aggravated by exposure to HDM or pollen \[[@B10][@B11]\]. In this context, we reported that *Df* or Der f 1 directly activate the effector functions of eosinophils, such as adhesion, superoxide anion (O~2~^-^) generation and degranulation \[[@B12]\], which may be the important mechanisms for induction or aggravation of allergic symptoms in nonsensitized patients. Protease activated receptor-2 on the eosinophils is involved in *Df* or Der f 1-induced eosinophil activation \[[@B12]\].

In a clinical setting, β2-adrenergic agonists, especially short-acting β2 agonists (SABA) such as salbutamol, are used in the treatment of asthma attacks to release airway obstruction \[[@B13]\]. In some cases, formoterol, a long-acting β2 agonist (LABA), is used with budesonide, an inhaled glucocorticoid (ICS), as a maintenance and reliever therapy for preventing or treating asthma exacerbation \[[@B14]\]. In addition to their bronchodilation effect, some β2-adrenergic agonists exert anti-inflammatory effects \[[@B15][@B16][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28][@B29]\]. In this study, we investigated whether the β2-adrenergic agonist could modify *Df*- and Der f 1-induced eosinophilic activation.

MATERIALS AND METHODS
=====================

Preparation of eosinophils and *Df*
-----------------------------------

Eosinophils were isolated from peripheral blood from nonallergic healthy volunteers with a blood differential eosinophil count of \<5%. Healthy volunteers were defined as subjects with no history of allergic disease, such as asthma or rhinitis, with no symptoms. The number of males and females was comparable among the donors. This study was approved by the Ethical Committee of Saitama Medical University (IRB number: 781-III), and written informed consent was obtained before collection of each blood sample. Eosinophils were isolated by negative selection using anti-CD16 Ab-coated magnetic beads (Miltenyi Biotec, Auburn, CA, USA), as previously described \[[@B12][@B27][@B28][@B29][@B30]\]. Over 98% of the cells were eosinophils, as determined by morphological criteria using May-Grünwald-Giemsa staining. Eosinophils were resuspended in Hanks\' balanced salt solution (HBSS) supplemented with gelatin to a final concentration of 0.1% (HBSS/gel). *Df* was collected and a dried extract prepared as previously described \[[@B31]\]. Der f 1, purified from mite culture by affinity chromatography, was obtained from Indoor Biotechnologies Inc. (Charlottesville, VA, USA).

Eosinophil adhesion
-------------------

The effect of formoterol or salbutamol on *Df* extract- or Der f 1-induced eosinophil adhesion to recombinant human (rh) intercellular adhesion molecule (ICAM) 1-coated plates was assessed based on the residual eosinophil peroxidase activity of adherent eosinophils, as previously described \[[@B12][@B27][@B28][@B29][@B30]\]. Briefly, eosinophils (100 µL of 1 × 10^5^ cells/mL in HBSS/gel) from nonallergic volunteers were preincubated with formoterol (1 μM) or salbutamol (1 μM) at 37^o^C for 20 minutes. Next, the cells were incubated in rh-ICAM-1-coated plates (10 µg/mL; R&D Systems, Minneapolis, MN, USA) in the presence or absence of *Df* extract (1 µg/mL) or Der f 1 (100 pg/mL) at 37 ^o^C for 20 minutes. Corresponding control wells were coated with HBSS/gel. The plates were washed with HBSS and 100 µL of HBSS/gel was then added to the wells. Standards comprised of 100 µL of serially diluted cell suspensions (1 × 10^3^, 3 × 10^3^, 1 × 10^4^, 3 × 10^4^, and 1 × 10^5^ cells/mL) were added to the empty wells. The eosinophil peroxidase substrate (1 mM o-phenylenediamine, 1 mM H~2~O~2~, and 0.1% Triton X-100 in Tris buffer, pH 8.0) was then added to all wells, and the plates were incubated for 30 minutes at room temperature. The reaction was stopped by adding 20 µL of 4 M H~2~SO~4~, and absorbance was measured at 490 nm. Each experiment was performed in quadruplicate using eosinophils from a single donor, and the percentage eosinophil adhesion was determined from mean values that were calculated from log dose-response curves. Eosinophil viability after incubation was \>98%, as determined by trypan blue dye exclusion.

Eosinophil O~2~^−^ generation
-----------------------------

Eosinophil O~2~^−^ generation was measured in 96-well enzyme-linked immunosorbent assay (ELISA) plates by superoxide dismutase (SOD)-inhibitable reduction of cytochrome C \[[@B12][@B27][@B28][@B29][@B30]\]. We initially added SOD (0.2 mg/mL in HBSS/gel; 20 µL) to SOD control wells and then HBSS/gel to all of the wells of rh-ICAM-1-coated plates (10 µg/mL) to bring the final volume to 100 µL. Eosinophils were pretreated with formoterol (1 μM) or salbutamol (1 μM) for 20 minutes. The density of eosinophils was adjusted to 1.25 × 10^6^ cells/mL of HBSS/gel mixed in a 4:1 ratio with cytochrome C (12 mg/mL of HBSS/gel), and 100 µL of eosinophil suspension was then added to all wells. Immediately following the addition of *Df* extract (1 µg/mL) to the eosinophils, the absorbance of the cell suspensions in the wells was measured at 550 nm (Immuno-Mini NJ-2300; Japan Intermed Co., Tokyo, Japan), followed by repeated measurements over the next 240 minutes (0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 210, 240 minutes). Each reaction was measured in duplicate and compared to control reactions in wells containing 20 µg/mL of SOD. The results were adjusted for a 1-mL reaction volume, and O~2~^−^ generation was calculated using an extinction coefficient of 21.1/mM/cm, as nanomoles of cytochrome C reduced per 1.0 × 10^6^ cells/mL minus the SOD control. The maximum value observed over the incubation period was determined to evaluate the effects of various factors on eosinophil O~2~^−^ generation. Cell viability, as determined by trypan blue exclusion at the end of each experiment, remained at 95% after 240 minutes of incubation.

Eosinophil degranulation
------------------------

Eosinophils (1 × 10^6^ cells/mL) in 96-well plates were incubated for the 240 minutes that were required for the measurement of O~2~^−^ generation before being immediately centrifuged (1,500 rpm) at 4^o^C for 10 minutes. Recovered cell-free supernatants were measured for eosinophil-derived neurotoxin (EDN), as described previously \[[@B12][@B27][@B28][@B29][@B30]\]. Concentrations of EDN were quantified by ELISA (Medical and Biological Laboratory Co. Ltd., Nagoya, Japan).

Statistical analysis
--------------------

Values are expressed as means ± standard error of the mean. Results were compared using a 1-way analysis of variance followed by the Tukey-Kramer test when differences were significant, or a paired *t* test for analysis of the differences between the 2 groups. Values of *p* \< 0.05 were considered statistically significant.

RESULTS
=======

Effect of formoterol or salbutamol on *Df* extract-induced eosinophil adhesion
------------------------------------------------------------------------------

First, we examined whether formoterol or salbutamol could modify *Df* extract-induced eosinophil adhesion. Eosinophils were preincubated with formoterol (1 μM) or salbutamol (1 μM) for 20 minutes, stimulated with or without *Df* extract (1 µg/mL), and adhesion to rh-ICAM-1 was evaluated. We previously reported that *Df* extract at a concentration of 1 µg/mL enhanced the adhesion of eosinophils to ICAM-1 \[[@B12]\], which was also confirmed in this study ([Fig. 1](#F1){ref-type="fig"}). We selected the concentration (1 μM) of formoterol or salbutamol in this study based on our previous findings \[[@B27][@B28]\]. Formoterol significantly suppressed *Df* extract-induced eosinophil adhesion to ICAM-1 ([Fig. 1](#F1){ref-type="fig"}; medium \[without formoterol or salbutamol\] 9.7% ± 1.9%, formoterol 5.6% ± 2.1%) (*p* \< 0.05). On the other hand, salbutamol did not modify the *Df* extract-induced eosinophil adhesion ([Fig. 1](#F1){ref-type="fig"}; salbutamol 9.9% ± 4.1%; not significant). In the absence of *Df* extract, neither formoterol nor salbutamol suppressed eosinophil adhesion to ICAM-1 ([Fig. 1](#F1){ref-type="fig"}).

![Effect of formoterol or salbutamol on *Dermatophagoides farinae* (*Df*) extract-induced eosinophil adhesion. Eosinophils from nonallergic volunteers were preincubated with or without formoterol (1 µM) or salbutamol (1 µM) for 20 min prior to analysis of adhesion to intercellular adhesion molecule-1 in the presence or absence of *Df* extract (1 µg/mL) (n = 7). FOR, formoterol; SAL, salbutamol.](apa-10-e15-g001){#F1}

Effect of formoterol or salbutamol on Der f 1-induced eosinophil adhesion
-------------------------------------------------------------------------

Next, we examined whether formoterol or salbutamol could modify Der f 1-induced eosinophil adhesion. Eosinophils were preincubated with formoterol (1 μM) or salbutamol (1 μM) for 20 minutes, stimulated with or without Der f 1 (100 pg/mL), and adhesion to rh-ICAM-1 was evaluated. We previously reported that Der f 1 at a concentration of 100 pg/mL enhanced the eosinophil adhesion to ICAM-1 \[[@B12]\]. Formoterol significantly suppressed Der f 1-induced eosinophil adhesion to ICAM-1 ([Fig. 2](#F2){ref-type="fig"}; medium 8.8% ± 2.8%, formoterol 5.6% ± 2.4%) (*p* \< 0.05), while salbutamol did not modify the Der f 1-induced eosinophil adhesion (salbutamol 7.1% ± 2.1%; not significant). In the absence of Der f 1, neither formoterol nor salbutamol suppressed eosinophil adhesion to ICAM-1 ([Fig. 2](#F2){ref-type="fig"}).

![Effect of formoterol or salbutamol on Der f 1-induced eosinophil adhesion. Eosinophils from nonallergic volunteers were preincubated with or without formoterol (1 µM) or salbutamol (1 µM) for 20 minutes prior to analysis of adhesion to intercellular adhesion molecule-1 in the presence or absence of Der f 1 (100 pg/mL) (n = 7). FOR, formoterol; SAL, salbutamol.](apa-10-e15-g002){#F2}

Effect of formoterol or salbutamol on *Df* extract-induced O~2~^−^ generation of eosinophils
--------------------------------------------------------------------------------------------

Next, we examined whether formoterol or salbutamol could modify *Df* extract-induced eosinophil O~2~^−^ generation. We previously reported that *Df* extract at a concentration of 1 μg/mL induced eosinophil O~2~^−^ generation in ICAM-1-coated plates \[[@B12]\], which we also confirmed in this study ([Fig. 3](#F3){ref-type="fig"}). Formoterol significantly suppressed *Df* extract-induced eosinophil O~2~^−^ generation ([Fig. 3](#F3){ref-type="fig"}; medium 1.50 ± 0.17 nmol/million cells, formoterol 1.04 ± 0.26 nmol/million cells) (*p* \< 0.05). On the other hand, salbutamol did not suppress the *Df* extract-induced eosinophil O~2~^−^ generation ([Fig. 3](#F3){ref-type="fig"}; salbutamol 1.70 ± 0.57 nmol/million cells; not significant).

![Effect of formoterol or salbutamol on *Dermatophagoides farinae (Df)* extract-induced eosinophil O~2~^−^ generation. Eosinophils were preincubated with or without formoterol (1 µM) or salbutamol (1 µM) for 20 min prior to analysis of O~2~^−^ generation of eosinophils in the presence or absence of *Df* extract (1 µg/mL) (n = 6). FOR, formoterol; SAL, salbutamol.](apa-10-e15-g003){#F3}

Effect of formoterol or salbutamol on *Df* extract-induced EDN release from eosinophils
---------------------------------------------------------------------------------------

Finally, we examined whether formoterol or salbutamol could modify *Df* extract-induced eosinophil degranulation. We previously reported that *Df* extract at a concentration of 1 μg/mL induced EDN release from eosinophils in ICAM-1-coated plates \[[@B12]\], which was also confirmed in this study ([Fig. 4](#F4){ref-type="fig"}). Formoterol, but not salbutamol, significantly suppressed the *Df* extract-induced EDN release from eosinophils ([Fig. 4](#F4){ref-type="fig"}; medium 154.3 ± 24.0 ng/mL, formoterol 93.0 ± 11.1 ng/mL; *p* \< 0.05, salbutamol 175.5 ± 34.3 ng/mL; not significant).

![Effect of formoterol or salbutamol on *Dermatophagoides farinae* (*Df*) extract-induced eosinophil eosinophil-derived neurotoxin (EDN) release. Eosinophils were preincubated with or without formoterol (1 µM) or salbutamol (1 µM) for 20 minutes prior to analysis of EDN release of eosinophils in the presence or absence of *Df* extract (1 µg/mL) (n = 6). FOR, formoterol; SAL, salbutamol.](apa-10-e15-g004){#F4}

DISCUSSION
==========

In this study, we found that formoterol, but not salbutamol, suppressed *Df*- or Der f 1-induced eosinophil adhesion to ICAM-1 when used at the same concentration. We also found that formoterol suppressed *Df*-induced eosinophil O~2~^−^ generation or EDN release in ICAM-1 coated plates. Since HDM exposure can induce or aggravate asthma symptoms, not only in HDM-sensitized patients, but also clinically in nonsensitized patients, the bronchodilation and such anti-inflammatory actions associate formoterol administration could be an effective strategy for asthma treatment.

In patients who, despite treatment with ICS, have persistent asthma symptoms, the addition of LABA to ICS is more useful than a higher dose of ICS alone \[[@B32]\]. The combination of ICS and LABA therapy (ICS/LABA) is now widely used for the treatment of moderate to severe asthma. Formoterol is a LABA that it is suited to the treatment of asthma or its exacerbation; for example, budesonide/formoterol (Symbicort, AstraZeneca, London, UK) maintenance and reliever therapy can be an important option for preventing or treating asthma exacerbation \[[@B14][@B33]\]. Furthermore, a recent study suggested that budesonide-formoterol used as needed for symptom relief is more effective at preventing severe exacerbations than maintenance low-dose budesonide plus as-needed terbutaline \[[@B34]\]. The Global Initiative for Asthma (2019) also recommends that ICS-formoterol reliever therapy be used as an alternative regimen to daily low-dose ICS in patients with mild asthma \[[@B13]\]. Thus, in addition to the bronchodilation effect associate with formoterol administration, it may have other benefits for the treatment of bronchial asthma.

Several studies have suggested that formoterol has anti-inflammatory properties *in vivo* \[[@B15][@B16][@B17][@B18]\], although some β2-adrenergic agonists, especially SABA, can increase eosinophilic airway inflammation and airway hyperresponsiveness \[[@B35][@B36][@B37]\]. For example, compared to budesonide alone, the addition of formoterol to budesonide suppressed the sputum eosinophil counts \[[@B15]\]. Formoterol suppressed neutrophilic airway inflammation in asthma \[[@B16]\], and formoterol, but not salbutamol, inhibited platelet activating factor (PAF)-induced eosinophil accumulation in the guinea-pig lung \[[@B17]\].

The presence of β2-adrenoreceptor receptors on inflammatory cells, such as mast cells, monocytes, neutrophils, eosinophils, T cells, and ILC2 \[[@B19][@B23][@B38]\], implies that formoterol may affect these cells through their β2-adrenergic receptors *in vitro*. As for eosinophils, Eda et al. \[[@B24]\] reported that formoterol concentrations greater than 1 μM inhibited PAF-induced eosinophil chemotaxis and degranulation. We previously reported that 1 µM formoterol, but not salbutamol, inhibited IL-5, leukotriene (LT) D~4~, or interferon-γ inducible protein of 10 kDa-induced eosinophil adhesiveness, O~2~^−^ generation and EDN release \[[@B27]\]. Furthermore, 1 µM formoterol, but not salbutamol, suppressed the periostin-induced eosinophil adhesion, O~2~^−^ generation and EDN release \[[@B28]\]. In this study, we also found that 1 µM formoterol, but not salbutamol, inhibited *Df*- or Der f 1-induced eosinophil adhesion to ICAM-1, *Df-*induced O~2~^−^ generation or EDN release. *Df* has components that have exhibit serine protease activity, whereas Der f 1 has cysteine protease activity \[[@B5][@B6]\]. Therefore, formoterol may suppress both serine protease and cysteine protease induced eosinophil adhesion. Furthermore, 1 μM formoterol appears to down-modulate the overall effector functions of eosinophils.

The involvement of the β2-adrenergic receptor in β2 agonist-mediated suppression of eosinophil functioning has not been fully clarified. For example, Kainuma et al. \[[@B25]\] reported that procaterol suppressed integrin expression on human eosinophils (CD11b, CD18, CD49d, CD29) when cocultured with epithelial cells, as well as the eosinophil-induced epithelial-to-mesenchymal transition of bronchial epithelial cells. Butoxamine, a specific β2-adrenergic antagonist, restored the suppression of eosinophil functions by procaterol \[[@B25]\], suggesting the involvement of β2-adrenergic receptor dependent mechanisms in the case of procaterol. Tachibana et al. \[[@B26]\] reported that fenoterol suppressed phorbol myristate acetate (PMA)-induced eosinophil O~2~^−^ generation. However, inhibition of PMA-induced O~2~^−^ generation by fenoterol was not reversed by ICI-118551 \[[@B26]\], a selective β2-adrenoreceptor antagonist, suggesting the involvement of mechanism independent from β2-adrenergic receptor in the case of fenoterol. As for formoterol, Bowden et al. \[[@B17]\] reported that ICI-118551 restored the formoterol-induced suppression of eosinophil or neutrophil adhesion to rat trachea. Therefore, although we did not examine the effect of β2-adrenoreceptor antagonists in this study, we consider that formoterol suppresses the function of eosinophils through β2-adrenergic receptors.

The exact mechanisms by which formoterol, but not salbutamol, suppressed *Df*-induced eosinophil effector functions remain unknown. One possibility is that levels of cyclic 3\',5\'-adenosine monophosphate (cAMP) in eosinophils, which are increased after β2-adrenoreceptor stimulation, differed between formoterol and salbutamol, and that increased cAMP in eosinophils or neutrophils suppressed the functions of these cells. For example, Kita et al. \[[@B39]\] reported that a cAMP analogue and cAMP phosphodiesterase inhibitors suppressed immunoglobulin-induced human eosinophil degranulation. They also reported previously that cAMP levels were inversely correlated with eosinophil degranulation \[[@B39]\]. Kainuma et al. \[[@B25]\] reported that forskolin, a part of adenylate cyclase, synthesis cAMP from adenosine triphosphate and thus suppresses integrin expression on human eosinophils, or eosinophil-induced epithelial-to-mesenchymal transition of bronchial epithelial cells. As for neutrophils, formoterol increased cAMP levels more than salbutamol \[[@B21][@B22]\], and inhibited neutrophil functions, including O~2~^−^ generation, LTB~4~ generation, and elastase release \[[@B21][@B22]\]. In fact, increased cAMP levels in neutrophils inhibited their adhesion \[[@B40]\]. Furthermore, in cultured rat cardiomyocytes, formoterol increased cAMP levels more than salbutamol \[[@B41]\]. Thus, formoterol is likely to increase cAMP levels in eosinophils more than salbutamol, and in so doing, can suppress eosinophil functions. Another possibility is that β2-adrenoreceptor-independent mechanisms may be involved in the suppression of *Df*-induced eosinophil effector functions by formoterol, as described above. Inhibition by β2-adrenergic agonists may include a component not mediated via the β2-adrenoreceptor.

A major limitation of this study is that all of the experiments were performed *in vitro* study. These agonists could have different concentration-response curve and receptor binding capacities. We did *in vitro* study with same concentration of these agonists. Therefore, it is difficult to conclude the general salbutamol invalidity, especially in the clinical setting. Furthermore, there is currently little information about formoterol concentrations in plasma or airways. For example, Campestrini et al. \[[@B42]\] reported that the plasma concentration of formoterol reached approximately about 300 pM after inhalation of 90 μg of formoterol. Gravett et al. \[[@B20]\] speculated that the local concentration of formoterol is approximately 10 nM if a maximal single dose of 24 μg, lung deposition of 18.6%, and a tidal volume of 500 mL is assumed. Although the actual concentration in the airway is difficult to estimate, concentrations greater than 1 μM at site of inflammation appear to be difficult to reach after β2-adrenoreceptor agonists treatment even during asthma attack. Another limitation is that we did not investigate the role of β2-adrenoreceptors in the suppression of eosinophil functions by formoterol. For example, we did not use selective β2-adrenoreceptor antagonists such as ICI-11855110 in this study, so whether the β2-adrenoreceptor-dependent or -independent pathway is involved in the suppression of *Df*-induced eosinophil activation by formoterol remains unknown.

In conclusion, we found that formoterol, but not salbutamol, suppressed *Df-* and Der f1-induced eosinophil adhesion to ICAM-1 when used at the same concentration. Furthermore, formoterol, but not salbutamol, suppressed *Df-*induced O~2~^−^ generation or EDN release. Therefore, formoterol may have both bronchodilation and anti-inflammatory effects, which can contribute to the treatment of bronchial asthma.
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